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E ffective antiplatelet therapy combining the inhibition of both thromboxane A 2 -dependent platelet aggregation and P2Y 12 receptors is necessary in patients undergoing percutaneous coronary intervention (PCI), particularly those with ST-segment elevation myocardial infarction (STEMI). Studies in this patient population have shown that the more intense P2Y 12 -receptor inhibition achieved with the use of prasugrel, ticagrelor, or cangrelor, as compared with clopidogrel, is associated with better clinical outcomes and a lower risk of stent thrombosis. [1] [2] [3] [4] [5] The benefit was obtained with in-hospital administration of these drugs, and it is not known whether earlier administration would be as safe and possibly more effective.
The concept of prehospital administration of antiplatelet agents in primary PCI was first investigated with the glycoprotein IIb/IIIa inhibitor abciximab, which was associated with a higher rate of Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 before primary PCI and lower rates of ischemic events, as compared with placebo. 6 Further studies confirmed the benefit of earlier administration of glycoprotein IIb/IIIa inhibitors in patients with STEMI, especially in those presenting very soon after symptom onset. [7] [8] [9] [10] [11] However, the benefit was less certain in patients at lower risk for ischemic events or presenting later. 12, 13 Various studies and meta-analyses suggested that pretreatment with clopidogrel in patients with STEMI could reduce the rate of ischemic events without excess bleeding, [14] [15] [16] but its effectiveness may be limited by its slow onset of action and the variable response. In contrast, the new oral P2Y 12 -receptor antagonists inhibit platelet function in less than 1 hour, which is compatible with transfer times for primary PCI. 17, 18 Although some studies suggested that the full effect of prasugrel or ticagrelor on platelet function may take several hours in patients with STEMI, [19] [20] [21] to our knowledge, these data have never been evaluated in relation to clinical outcomes.
Ticagrelor is a direct-acting inhibitor of the platelet P2Y 12 receptor with a rapid antiplatelet effect. 17, 22 It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with clopidogrel, 23 and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI. 24 The aim of the ATLANTIC (Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery) study was to evaluate whether early, in-ambulance administration of ticagrelor could safely improve coronary reperfusion in patients with STEMI transferred for primary PCI.
ME THODS

STUDY DESIGN AND PATIENTS
The ATLANTIC study was a phase 4, international, randomized, double-blind study. 25 Patients were randomly assigned to receive either prehospital (in the ambulance) or in-hospital (in the catheterization laboratory) treatment with ticagrelor, in addition to aspirin and standard care. The clinical study protocol is available with the full text of this article at NEJM.org. The coordinating center was the Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group at Pitié-Salpêtrière Hospital. The trial design and protocol were approved by the national regulatory authorities in all the participating countries and by the local ethics committee or institutional review board at each participating site. All the patients provided written informed consent.
Eligible patients, identified by ambulance personnel after STEMI had been diagnosed, had a symptom duration of more than 30 minutes but less than 6 hours, with an expected time from the qualifying electrocardiogram (ECG) to the first balloon inflation of less than 120 minutes. Randomization and the first loading dose of the study drug took place immediately after the diagnostic ECG and before the administration of a loading dose of any P2Y 12 -receptor antagonist. Patients were then transferred to a hospital to undergo coronary angiography, with or without PCI.
STUDY PROCEDURES
In the prehospital group, patients received a 180-mg loading dose of ticagrelor before transfer and then a matching placebo in the catheterization laboratory. Patients in the in-hospital group received a placebo before transfer and then a 180-mg loading dose of ticagrelor in the catheterization laboratory. All the patients subsequently received ticagrelor at a dose of 90 mg twice daily for 30 days, with a recommendation that treatment be continued for a total of 12 months. In-ambulance use of glycoprotein IIb/IIIa inhibitors was discouraged but was left to the physician's discretion. In-laboratory use of glycoprotein IIb/IIIa inhibitors after angiography had to be identified as either a strategy of choice or a bailout treatment during PCI. A pharmacodynamic substudy was conducted at five participating centers, the main end point of which was the result of a phosphorylation assay for measuring the platelet-reactivity index of a vasodilator-stimulated phosphoprotein at the start of catheterization (before PCI). 25 
STUDY END POINTS
The coprimary end points were the proportion of patients who did not have 70% or greater resolution of ST-segment elevation before PCI and the proportion of patients who did not meet the criteria for TIMI flow grade 3 in the infarct-related artery at angiography before PCI. Prespecified secondary end points included the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization at 30 days; definite stent thrombosis at 30 days; thrombotic bailout with glycoprotein IIb/IIIa inhibitors; TIMI flow grade 3 at the end of the procedure; and complete (≥70%) resolution of ST-segment elevation at 60 minutes after PCI.
Safety end points included major bleeding, Reasons for exclusion from the modified intention-to-treat population included nonreceipt of study medication (in three patients in the prehospital group and in one in the in-hospital group). In the safety analysis, data were analyzed according to the study medication actually received. Reasons for exclusion from the safety population included nonreceipt of study medication as well as receipt of study medication in an incorrect order (i.e., not according to the randomized assignment; in one patient in the prehospital group and in three in the in-hospital group). Data from patients who could not be evaluated for TIMI flow grade or for resolution of ST-segment elevation may be reported in more than one category of missing data. 25 Centralized, blinded reviews of angiographic data and ECG recordings were conducted by Cardialysis Core Laboratory services (Rotterdam, the Netherlands) and eResearch Technology (ERT; Peterborough, United Kingdom), respectively. An independent adjudication committee, whose members were unaware of the treatment assignments, reviewed the clinical end points, except deaths and minimal bleeding events (see the Supplementary Appendix, available at NEJM.org).
STUDY OVERSIGHT AND FUNDING
The executive and steering committees (see the Supplementary Appendix) oversaw the conduct of the trial and data analysis, in collaboration with representatives of the study sponsor (AstraZeneca). The trial was monitored by an independent data and safety monitoring board (see the Supplementary Appendix). Data were collected and analyzed by Worldwide Clinical Trials (London) according to the protocol and the predefined statistical analysis plan. The chair of the executive committee (the first author) had unrestricted access to the data after the database was locked, and statistical analyses were performed independently by one of the academic authors, who is a statistician for the ACTION study group. The first author prepared the first draft of the manuscript; all the authors revised the manuscript and made the decision to submit it for publication. All the authors assume responsibility for the accuracy and completeness of the data and analyses reported and for the fidelity of the study to the protocol. Medical-writing support, funded by AstraZeneca, was provided by Prime Medica.
STATISTICAL ANALYSIS
We calculated that the study would have 80% power to detect a difference of 6 percentage points (40% relative difference) between the two groups in the complete resolution of ST-segment elevation, assuming a 15% rate of complete resolution in the control group (i.e., patients who received the initial loading dose of ticagrelor in the hospital). 24 The study was also adequately powered to assess differences regarding TIMI flow before PCI. 25 Efficacy analyses were performed in the modified intention-to-treat population, defined as all the patients who underwent randomization and received at least one dose of the study drug. Patients with missing data for either ST-segment elevation or TIMI flow grade were excluded from * Plus-minus values are means ±SD. There were no significant between-group differences in the baseline characteristics listed here. For further details, see Table S2 in the Supplementary Appendix. CABG denotes coronary-artery bypass grafting, and PCI percutaneous coronary intervention. † The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. ‡ Thrombolysis in Myocardial Infarction (TIMI) risk scores assess the prognosis for patients with acute coronary syndromes on a scale from 0 to 14, with higher scores indicating greater risk. § The location of care at the time of randomization was unknown for one patient in the in-hospital group. First medical contact was defined as occurring either in the ambulance (primary transfer to an appropriate hospital setting) or in an emergency department before ambulance transfer (secondary transfer to an appropriate hospital setting). ¶ Patients may have received more than one type of stent. ‖ Data on glycoprotein IIb/IIIa inhibitor use (before and after PCI) were missing for two patients in the prehospital group. ** Combination therapy was defined as a sequence of prescriptions for different anticoagulants, with changes in anticoagulant use during the hospitalization phase.
The 6 the analysis of the two coprimary end points. For each end point, the treatment groups were compared with the use of a logistic-regression model with treatment as an exploratory variable. A Holm procedure to correct for multiple comparisons, which included the adjustment of significance level and sequential testing, was used to control the overall type I error rate of 5% in testing the two coprimary end points. Subgroup analyses to evaluate variations in treatment effect were performed with the use of the logistic-regression model and with terms for treatment, subgroup, and interaction of treatment with subgroup. P values were not adjusted for these analyses.
Secondary end points (clinical end points, resolution of ST-segment elevation or TIMI flow at the end of the procedure, and thrombotic bailout with glycoprotein IIb/IIIa inhibitors) were examined with the use of an analysis identical to that described for the coprimary end points. KaplanMeier estimates of clinical end points were also calculated for the first 30 days after the first dose. Since no prespecified hypothesis was made, statistical testing of all secondary efficacy variables, including the clinical end points, was considered to be exploratory, and no hierarchical rule for tests or adjustment was used.
The safety analysis included all the patients who received at least one dose of the study drug. Adjudicated bleeding events were summarized separately, according to the protocol definition (PLATO criteria) and other prespecified definitions.
R ESULT S
PATIENTS AND PROCEDURES
Between September 12, 2011, and October 3, 2013, a total of 1875 patients were enrolled in the * Data include the total number of patients who had data that could be evaluated. Data were missing as follows: TIMI flow grade for 178 patients (82 patients in the prehospital group and 96 in the in-hospital group), prehospital ST-segment elevation for 16 (8 in each treatment group), and pre-PCI ST-segment elevation for 212 (112 in the prehospital group and 100 in the in-hospital group). Before arrival at the hospital, 51 patients had no clinically significant ST elevation and therefore could not be evaluated for resolution of ST-segment elevation (18 patients in the prehospital group and 33 in the in-hospital group). ST-segment resolution was calculated as the combination of two electrocardiographic (ECG) variables (ST segment at index ECG and ST segment before PCI). † The odds ratios for the prehospital group versus the in-hospital group, two-sided 95% confidence intervals, and P values were calculated from a logistic-regression model, with treatment as the only explanatory variable. ‡ The difference in binomial proportions was calculated as the proportion in the prehospital group minus the proportion in the in-hospital group. 
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ATLANTIC study, of whom 1862 provided written informed consent and were randomly assigned to either prehospital ticagrelor (909 patients) or in-hospital ticagrelor (953 patients). Randomization was performed by 102 ambulance services, followed by transfer to 112 PCI centers in 13 countries (Table S1 in the Supplementary Appendix). Reasons for discontinuation and for exclusion from the analyses are shown in Figure 1 . The characteristics of the patients at baseline were well balanced between the two groups, with a numerically small, nonsignificant imbalance with respect to a TIMI risk score of more than 6 (Table 1, and Table S2 in the Supplementary Appendix). The first medical contact was in the ambulance for more than 75% of the patients; the first medical contact for the remaining patients was in an emergency department, before ambulance transfer. Coronary angiography was performed primarily by means of radial access (in 67.3% of the patients who underwent coronary angiography), and PCI was performed in 87.5% of the patients ( Table 1) .
The median times from symptom onset to STEMI diagnosis, from randomization to angiography, and between the two loading doses (i.e., prehospital vs. in-hospital), were 73, 48, and 31 minutes, respectively (Fig. S1 in the Supplementary Appendix). The first and second loading doses of study medication were administered to more than 99% and 95% of the patients, respectively, and nearly 99% received at least one dose of aspirin ( Table 1 ). The majority of patients with STEMI received maintenance treatment with ticagrelor (85.6% of patients) and aspirin (92.5%). Just over one third of patients received a glycoprotein IIb/IIIa inhibitor.
EFFICACY
Platelet reactivity was reduced significantly and progressively after the administration of ticagrelor in both study groups in the pharmacodynamic substudy, which included 37 patients. There was no significant difference between prehospital and in-hospital administration of ticagrelor at any time point, with the maximum numerical difference between the treatment groups being observed 1 hour after PCI (Fig. S2 and S3 in the Supplementary Appendix).
There was no significant difference between the prehospital group and the in-hospital group in terms of the proportion of patients who did not have a 70% or greater resolution of ST-segment elevation before PCI (odds ratio with prehospital vs. in-hospital administration of the loading dose of ticagrelor, 0.93; 95% confidence interval [CI], 0.69 to 1.25; P = 0.63) and the proportion of patients who did not have a TIMI flow of grade 3 in the infarct-related artery at initial angiography (odds ratio, 0.97; 95% CI, 0.75 to 1.25; P = 0.82) ( Table 2 ). The absence of 70% or greater resolution of ST-segment elevation 1 hour after PCI was reported for 42.5% of patients in the prehospital group and 47.5% of those in the in-hospital group (P = 0.055), and the absence of TIMI flow grade 3 in the culprit artery was reported for 17.8% and 19.6% of the patients, respectively (P = 0.34). The results were consistent across quartiles of time from the first loading dose to the ECG or angiogram obtained before PCI, corresponding to different transfer times (data not shown). The results were also consistent for both coprimary end points across prespecified subgroups, except for the subgroup of patients in whom morphine was administered (Fig. S4 in the Supplementary Appendix). The primary end point of ST-segment resolution was significantly improved with prehospital administration of ticagrelor in patients not receiving morphine (P = 0.005 for interaction). 
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There were no significant differences between the two groups for the composite end point of death, myocardial infarction, stroke, urgent coronary revascularization, or stent thrombosis (Fig. S5 in (Fig. 2 and Table 3 ). There was no clear relationship between type of anticoagulation and the occurrence of stent thrombosis (Table S3 in the Supplementary Appendix).
A total of 30 patients (3.3%) in the prehospital group and 19 (2.0%) in the in-hospital group died (P = 0.08). The most common causes of death were cardiogenic shock, cardiac arrest, mechanical complication, and heart failure ( Table S4 in the Supplementary Appendix).
SAFETY
Rates of bleeding events that were not related to coronary-artery bypass grafting were low during the first 48 hours after the initial dose and from 48 hours through 30 days, and the rates did not differ significantly between the two study groups ( Table 3) . The results were consistent across all the definitions and types of bleeding adjudicated by the clinical end-point committee (Table S5 in the Supplementary Appendix). There was no significant difference in the rates of bleeding events between the two study groups among the 11.1% of patients who did not undergo revascularization or among the 8.6% of patients who did not have a final diagnosis of STEMI. There was no imbalance between the two treatment groups in terms of serious adverse events.
DISCUSSION
Prehospital treatment of ongoing STEMI with fibrinolytic agents or glycoprotein IIb/IIIa inhibitors has been associated with improved coronary reperfusion and outcomes. 6, 8, [26] [27] [28] [29] The present study shows that the administration of the potent P2Y 12 -receptor antagonist ticagrelor shortly before PCI does not improve reperfusion of the culprit artery before the procedure but is safe and may prevent postprocedural acute stent thrombosis. The observed preventive benefit is consis- -tent with pharmacodynamic and ECG findings suggesting that the maximal effect of prehospital administration of ticagrelor occurs after the end of the procedure. Pretreatment (i.e., before coronary angiography) with glycoprotein IIb/IIIa inhibitors or P2Y 12 -receptor antagonists in patients with non-ST-segment elevation (NSTE) acute coronary syndromes has been associated with excess bleeding, without a reduction in ischemic complications, 18, 30, 31 leading to guideline recommendations against the use of these agents in such patients. 32, 33 There is limited information on pretreatment with clopidogrel in patients with STEMI undergoing PCI, but the available data suggest that there is no safety issue and that the rate of major adverse cardiovascular events may be reduced. 14, 15 The ATLANTIC study shows that the early administration of ticagrelor in patients with STEMI is safe, regardless of the definition of bleeding used. This favorable safety profile may be related to the high likelihood of both confirmation of the diagnosis of STEMI and treatment with PCI and placement of a stent; in contrast, the diagnosis of NSTE acute coronary syndrome in patients presenting with transient chest pain is often not confirmed, and PCI is not performed in 30 to 60% of such patients. 34, 35 The rate of stent thrombosis was reduced with prasugrel or ticagrelor in the STEMI cohorts in the pivotal trials comparing these agents with clopidogrel 1, 36 ; whether earlier administration of these drugs could further reduce the risk was unknown. In this study, all the stent-thrombosis events within the first 24 hours occurred in the in-hospital group, and the difference remained significant in favor of prehospital administration of ticagrelor for up to 30 days. Although our platelet-reactivity results lack statistical power, the maximal difference in platelet inhibition occurred concomitantly with the reduction of stent thrombosis, the findings being supportive of one another. Stent thrombosis has been under scrutiny, and the excess of early stent-thrombosis events observed consistently across trials with bivalirudin [37] [38] [39] has been seen largely as a reason for limiting its use. In our study, the rate of definite stent thrombosis was reduced without a safety trade-off. Although prespecified, stent thrombosis was a secondary end point among neutral study results; therefore, this finding should not be interpreted as definitive.
Mortality was reduced with ticagrelor, as compared with clopidogrel, in the large PLATO trial. 23 In the ATLANTIC trial, mortality was low and there was a nonsignificant numerical excess of deaths in the prehospital group. Almost all the deaths were due to cardiogenic shock, cardiac arrest, or cardiac rupture rather than to bleeding or ischemic events. This finding may reflect the fact that ambulance crews did not exclude the sickest patients from the study, and we cannot rule out an imbalance between the two study groups in terms of the severity of the presenting event (e.g., a higher TIMI risk score in the prehospital group). Our study has limitations inherent in the sample size and the short intervals between administration of the study drug and reperfusion. There is consistency across the data on pharmacodynamics, ST-segment resolution, and TIMI flow grade, which suggests that most of the drug effect occurred after PCI. The time to PCI in our study was extremely short in both groups, indicating excellent practice, but this may have blunted the drug effect and may not reflect routine practice. Another potential limitation is related to the delayed absorption of orally administered P2Y 12 -receptor antagonists. [19] [20] [21] The onset of action may have been delayed further by morphine coadministration in half the study population. 21, 40 Patients who did not receive morphine had a significant improvement in the ECG-based primary end point, with a significant P value for interaction between morphine use and time of ticagrelor administration. The extent to which this interaction may have affected our results remains unknown at this stage.
In conclusion, prehospital administration of ticagrelor a short time before PCI in patients presenting with ongoing STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion. 
